Medicare now covers GLP-1s for $50/mo copay
See if you qualify by answering a few simple questions and get a prescription shipped to your door.
- Medicare now covers certain GLP-1 weight loss medications.
- If you qualify, you can get Wegovy®, Zepbound®, or Foundayo™ through Noom for $50 per month.
- We check your eligibility, handle the paperwork and, if eligible, medication will be shipped directly to your home.
Noom makes it easy for
Medicare members
Lose up to 20% of your body weight with
FDA-approved GLP-1 medications*
*NOTE: Your provider chooses the right medication for you based on your health history. Not all medications are right for every person. In a 68- and 72-week clinical trial studying Wegovy (2.4 mg) and Zepbound (15 mg) in patients without diabetes and with BMI >= 30, or BMI >= 27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone).
You may qualify if you have
Medicare Part D and meet one
of these conditions
BMI OF
35+
You may qualify. No other health conditions needed.
BMI OF
30+
You may qualify if you also have one of these:
- Heart failure
- High blood pressure that is hard to control
- Kidney disease (stage 3a or above)
BMI OF
27+
You may qualify if you also have one of these:
- Pre-diabetes
- History of heart attack or stroke
- Symptomatic peripheral artery disease
Want to see if your GLP-1 medications are
covered under the Medicare Bridge program?
Qualifying is not guaranteed. All members must go through a prior authorization
process. A doctor reviews your information before prescribing any medication.
Here’s exactly
what you’ll pay
We want to be
clear about costs
before you start
There are three separate costs to consider.
We want to be clear about
costs before you start
There are three separate costs to consider.
$39
This covers your first evaluation with a Noom clinician, done entirely online.
Your Noom Med plan
$99/mo‡
This covers your care team, the Noom app, and ongoing clinical support.
Your medication
$50 per fill
This is billed through your Medicare Bridge benefit. It applies every time your prescription is filled — at any dose.
After that, the ongoing cost is your monthly $50 copay (per fill) + $297 billed every 12 weeks for your Noom Med plan.
This is not a free program. Medicare covers the cost of the medication, but you still pay a $50 copay per fill. You also pay for your Noom Med plan separately. These costs are not covered by Medicare.
Medication works better when you have support
GLP-1 medications help you feel less hungry. But building new habits is what makes the results last. Noom pairs your GLP-1 medication with a daily program that helps you eat better, move more, and feel in control. It is not a diet. It is a way of thinking differently about food and your health.
more weight in 6 months than people who take the medication alone.*
Frequently Asked Questions
See if Medicare covers your
weight loss medication
It takes just a few minutes to find out. Answer some questions about your health and your Medicare coverage. Our clinical team will review your information and let you know whether you may qualify. The whole process is online.
- Noom Med is a health care program run by Noom Health. It is not a Medicare plan, Medicare Advantage plan, or Part D drug plan. Noom is not part of Medicare. Noom is not approved or endorsed by Medicare, the Centers for Medicare & Medicaid Services (CMS), or any government agency.thereafter. New pricing for new accounts only effective as of March 31, 2026.
- The $50 copay per fill does not count toward your Part D deductible or your annual out-of-pocket maximum.
- Wegovy® is a trademark of Novo Nordisk. Zepbound® and Foundayo® are trademarks of Eli Lilly and Company.
*Results based on a January 2026 analysis of 14,203 Noom GLP-1Rx Program members who actively logged weight over a 40 week period. High and low engagement groupings measured by quantile of app opens. Higher app engagement was associated with greater weight loss at 16 weeks; this association does not imply causation.
†Based on a retrospective study of self-reported data of active versus passive users. In clinical trials, Wegovy® and Zepbound® users lost 15% and 20% of their body weight with changes in diet and exercise. Results vary
